ID   HepAD79
SY   Hep AD79; HepG2-AD79; AD-79; AD79
DR   Wikidata; Q54882831
RX   PubMed=9875378;
CC   Population: Caucasian.
CC   Characteristics: Inducibly expresses a lamivudine-resistant HBV genome under the control of a tet operator/CMV promoter. Upon removal of tetracycline the cell line produces viral RNA and secrete virus-like particles into the supernatant.
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from sampling site: Liver.
DI   NCIt; C3728; Hepatoblastoma
DI   ORDO; Orphanet_449; Hepatoblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_0027 ! Hep-G2
SX   Male
AG   15Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 20-05-21; Version: 11
RX   PubMed=9875378;
RA   Ladner S.K., Miller T.J., Otto M.J., King R.W.;
RT   "The hepatitis B virus M539V polymerase variation responsible for 3TC
RT   resistance also confers cross-resistance to other nucleoside
RT   analogues.";
RL   Antivir. Chem. Chemother. 9:65-72(1998).